In multiple clinical trials of Venetoclax and HMA or LDAC, TP53 mutation was found to be the predominant mutation in the AML patients that did not respond to Venetoclax-based therapy (7/20 cases)[32]. The gene discussed is TP53; the disease is acute myeloid leukemia.